Navigation Links
Sheep Anti-Human CATHEPSIN G Polyclonal Antibody, Unconjugated from AbD Serotec

ProductsSheep Anti-Human CATHEPSIN G Polyclonal Antibody, Unconjugated from AbD Serotec
Company AbD Serotec
Item Sheep Anti-Human CATHEPSIN G Polyclonal Antibody, Unconjugated
Price $260.00
Description SHEEP ANTI HUMAN CATHEPSIN G
Info AbD SerotecAbD Serotec

UK & Ireland
MorphoSys UK Ltd
Endeavour House
Langford Business Park
Langford Lane
Kidlington
Oxford, OX5 1GF, UK
Tel: +44(0)1865 852 700
Fax: +44(0)1865 852 739
E-mail: sales@ab-direct.com

North & South America
MorphoSys US Inc
3200 Atlantic Avenue, Suite 125
Raleigh, NC 27604, USA
Toll Free: 1-800-265-7376
Tel: 919-878-7978
Fax: 919-878-3751
E-mail: sales.us@ab-direct.com

Scandinavia & Baltic States
MorphoSys UK Ltd (Scandinavia)
Postboks 4079
N-2306 HAMAR, Norway
Tel: +44 (0)1865 852 728
Fax: +44 (0)1865 852 739
E-mail: sales.no@ab-direct.com

France & Belgium
MorphoSys UK Ltd (France)
15 rue des Pas Perdus
BP 38338
95804 Cergy Saint-Christophe
France
Tel: + 33 1 34 25 83 34
Fax: + 33 1 34 25 44 00
E-mail: sales.fr@ab-direct.com

Germany, Netherlands, Austria & Switzerland
MorphoSys AbD GmbH
Immermannstr. 13
D-40210 Dsseldorf
Germany
Tel (General): +49 (0)211 93 503 10
Tel (Technical): +49 (0)211 93 503 11
Fax: +49 (0)211 93 503 12
E-mail: sales.de@ab-direct.com

Worldwide
MorphoSys UK Ltd
Endeavour House
Langford Business Park
Langford Lane
Kidlington
Oxford, OX5 1GF, UK
Tel: +44(0)1865 852 700
Fax: +44(0)1865 852 739
E-mail: sales@ab-direct.com

Customer Service: 1-800-265-7376
Fax Number: 1-919-878-3751
Web Site: www.ab-direct.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. Sheep Anti-Bovine BETA-LACTOGLOBULIN A Polyclonal Antibody, Unconjugated from AbD Serotec
2. Sheep Anti-Digoxigenin Fab fragments Antibody, AP Conjugated from Roche Applied Science
3. Sheep Anti-Salmonella Thomasville Polyclonal Antibody, Unconjugated from Abcam
4. Sheep Anti-Salmonella Shoreditch Polyclonal Antibody, Unconjugated from Abcam
5. Sheep Anti-Human ErbB 2 Polyclonal Antibody, Unconjugated from Abcam
6. Anti-Sheep/Goat Sac-Cel - Solid-phase Separation System from IDS Ltd
7. Sheep Anti-Decorin Polyclonal Antibody, Unconjugated from Abcam
8. Sheep Anti-Mouse TREM-2 Polyclonal Antibody, Unconjugated from R&D Systems
9. Sheep Anti-Human IDO Monoclonal Antibody,, Clone ZMD.420 from Invitrogen
10. Sheep Serum from CHEMICON
11. Sheep Anti-Rabbit Tryptophan Hydroxylase Antibody, Unconjugated from ABR-Affinity BioReagents
Breaking Biology News(10 mins):MSU researcher unveils new approach to treat lower back pain 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4Superior offspring without genetic modification 2Johns Hopkins leads first 16 patient multicenter domino donor kidney transplant 51007 1Johns Hopkins leads first 16 patient multicenter domino donor kidney transplant 51007 2Johns Hopkins leads first 16 patient multicenter domino donor kidney transplant 51007 3DaVitas Award Winning Training Program for New Teammates Reaches Milestone With 100th DaVita Academy in Baltimore Maryland 51006 1DaVitas Award Winning Training Program for New Teammates Reaches Milestone With 100th DaVita Academy in Baltimore Maryland 51006 2Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 1Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 2Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 3Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 4Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 5Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 6Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 7Denosumab Demonstrates Superiority Over Zometa 28R 29 in Pivotal Phase 3 Head to Head Trial in Breast Cancer Patients With Bone Metastases 4698 8